The estimated Net Worth of W. Michael Flanagan is at least $2.5 millió dollars as of 17 June 2024. Dr Flanagan owns over 10,106 units of Avidity Biosciences stock worth over $2,058,013 and over the last 4 years he sold RNA stock worth over $437,275.
Dr has made over 2 trades of the Avidity Biosciences stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 10,106 units of RNA stock worth $395,448 on 17 June 2024.
The largest trade he's ever made was selling 10,106 units of Avidity Biosciences stock on 17 June 2024 worth over $395,448. On average, Dr trades about 2,373 units every 25 days since 2021. As of 17 June 2024 he still owns at least 50,765 units of Avidity Biosciences stock.
You can see the complete history of Dr Flanagan stock trades at the bottom of the page.
Dr. W. Michael Flanagan Ph.D. is the Chief Technical Officer at Avidity Biosciences.
Dr D is 59, he's been the Chief Technical Officer of Avidity Biosciences since . There are 3 older and 3 younger executives at Avidity Biosciences. The oldest executive at Avidity Biosciences, Inc. is Dr. Frank McCormick Ph.D., 71, who is the Scientific Founder & Member of Scientific Advisory Board.
W's mailing address filed with the SEC is C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Avidity Biosciences have traded over $8,545,325 worth of Avidity Biosciences stock and bought 2,050,000 units worth $36,900,000 . The most active insiders traders include Investments, Lpwong Roderic..., Lilly & Co Eli és Asset Management, Lp Chen B.... On average, Avidity Biosciences executives and independent directors trade stock every 34 days with the average trade being worth of $3,142,336. The most recent stock trade was executed by Arthur A Levin on 19 August 2024, trading 5,000 units of RNA stock currently worth $6,200.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences executives and other stock owners filed with the SEC include: